We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , along with partner Sanofi (SNY - Free Report) , announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking label expansion of blockbuster drug Dupixent (dupilumab) for yet another indication.
The sBLA is seeking approval of Dupixent for the treatment of eosinophilic esophagitis (EoE) in patients aged 12 years and above in the United States.
With the FDA granting a priority review to the sBLA, a decision from the regulatory body is expected on Aug 3, 2022.
If approved, Dupixent will become the first medicine to treat EoE in the United States.
The above-mentioned sBLA was based on data from two phase III studies that evaluated the safety and efficacy of Dupixent’s 300 mg weekly dose for treating EoE in patients aged 12 years and above, as well as data from an active long-term extension study.
Data from the same showed treatment with Dupixent significantly improved the signs and symptoms of EoE versus placebo at 24 weeks, including the ability to swallow and the reduction in eosinophil count in the esophagus.
Shares of Regeneron have rallied 10% so far this year against the industry’s decline of 10.7%.
Image Source: Zacks Investment Research
The FDA has granted a Breakthrough Therapy designation to Dupixent for the treatment of patients aged 12 years and older with EoE in September 2020.
Dupixent is being jointly marketed by Regeneron and Sanofi under a global collaboration agreement. Sanofi records global net product sales of Dupixent while Regeneron records its share of profits/losses in connection with global sales of the drug.
In 2021, Dupixent generated global sales worth $6.2 billion, reflecting an increase of 53% year over year.
Dupixent is approved in the United States, the EU and some other countries for type II inflammatory diseases, namely uncontrolled chronic rhinosinusitis with nasal polyposis, moderate-to-severe asthma and moderate-to-severe atopic dermatitis. The frequent label expansion approvals are driving the drug’s sales higher.
Dupixent has become the key driver of Sanofi’s top line and profits for Regeneron. Both companies are also studying dupilumab in late-stage studies in a broad range of diseases driven by type 2 inflammations like chronic obstructive pulmonary disease, bullous pemphigoid, chronic spontaneous urticaria and some more.
The Zacks Consensus Estimate for Athersys’ earnings has been revised 21.7% upward for 2022 over the past 60 days.
Earnings of ATHX surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions, delivering an average earnings surprise of -25.89%.
vTv Therapeutics’ loss per share estimates have narrowed 39.4% for 2022 over the past 60 days.
Earnings of VTVT surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion, delivering an average surprise of 26.79%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , along with partner Sanofi (SNY - Free Report) , announced that the FDA has accepted the supplemental biologics license application (sBLA) seeking label expansion of blockbuster drug Dupixent (dupilumab) for yet another indication.
The sBLA is seeking approval of Dupixent for the treatment of eosinophilic esophagitis (EoE) in patients aged 12 years and above in the United States.
With the FDA granting a priority review to the sBLA, a decision from the regulatory body is expected on Aug 3, 2022.
If approved, Dupixent will become the first medicine to treat EoE in the United States.
The above-mentioned sBLA was based on data from two phase III studies that evaluated the safety and efficacy of Dupixent’s 300 mg weekly dose for treating EoE in patients aged 12 years and above, as well as data from an active long-term extension study.
Data from the same showed treatment with Dupixent significantly improved the signs and symptoms of EoE versus placebo at 24 weeks, including the ability to swallow and the reduction in eosinophil count in the esophagus.
Shares of Regeneron have rallied 10% so far this year against the industry’s decline of 10.7%.
Image Source: Zacks Investment Research
The FDA has granted a Breakthrough Therapy designation to Dupixent for the treatment of patients aged 12 years and older with EoE in September 2020.
Dupixent is being jointly marketed by Regeneron and Sanofi under a global collaboration agreement. Sanofi records global net product sales of Dupixent while Regeneron records its share of profits/losses in connection with global sales of the drug.
In 2021, Dupixent generated global sales worth $6.2 billion, reflecting an increase of 53% year over year.
Dupixent is approved in the United States, the EU and some other countries for type II inflammatory diseases, namely uncontrolled chronic rhinosinusitis with nasal polyposis, moderate-to-severe asthma and moderate-to-severe atopic dermatitis. The frequent label expansion approvals are driving the drug’s sales higher.
Dupixent has become the key driver of Sanofi’s top line and profits for Regeneron. Both companies are also studying dupilumab in late-stage studies in a broad range of diseases driven by type 2 inflammations like chronic obstructive pulmonary disease, bullous pemphigoid, chronic spontaneous urticaria and some more.
Zacks Rank & Stocks to Consider
Regeneron currently carries a Zacks Rank #3 (Hold). Stocks worth considering in the biotech sector are Athersys, Inc. , and vTv Therapeutics Inc. (VTVT - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Athersys’ earnings has been revised 21.7% upward for 2022 over the past 60 days.
Earnings of ATHX surpassed estimates in one of the trailing four quarters and missed the same on the other three occasions, delivering an average earnings surprise of -25.89%.
vTv Therapeutics’ loss per share estimates have narrowed 39.4% for 2022 over the past 60 days.
Earnings of VTVT surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion, delivering an average surprise of 26.79%.